Jan Malcolm Sells 50 Shares of United Therapeutics (NASDAQ:UTHR) Stock

by · The Cerbat Gem

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) Director Jan Malcolm sold 50 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $512.12, for a total value of $25,606.00. Following the completion of the sale, the director owned 420 shares in the company, valued at approximately $215,090.40. This trade represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Jan Malcolm also recently made the following trade(s):

  • On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $482.98, for a total value of $24,149.00.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $513.99 on Thursday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99. The stock’s 50 day moving average price is $468.27 and its two-hundred day moving average price is $384.93. The stock has a market capitalization of $22.13 billion, a price-to-earnings ratio of 19.48, a PEG ratio of 5.07 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same period last year, the company earned $6.39 earnings per share. The firm’s revenue was up 6.8% compared to the same quarter last year. On average, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on UTHR shares. Oppenheimer raised their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. UBS Group increased their price target on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Wells Fargo & Company boosted their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Cantor Fitzgerald upped their price objective on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Finally, Royal Bank Of Canada increased their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $505.00.

Check Out Our Latest Stock Report on United Therapeutics

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. Darwin Global Management Ltd. bought a new position in shares of United Therapeutics during the 3rd quarter worth approximately $317,617,000. Norges Bank bought a new position in United Therapeutics during the second quarter worth $136,453,000. Invesco Ltd. increased its holdings in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares during the last quarter. AQR Capital Management LLC raised its position in shares of United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the period. Finally, Amundi lifted its stake in shares of United Therapeutics by 198.8% during the 1st quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock worth $107,635,000 after buying an additional 232,988 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Featured Stories